The 5q31 variants associated with psoriasis and Crohn’s disease are distinct

Yonghong Li1,*, Monica Chang1, Steven J. Schrodi1, Kristina P. Callis-Duffin2, Nori Matsunami3, Daniel Civello1,†, Nam Bui1, Joseph J. Catanese1, Mark F. Leppert3,4, Gerald G. Krueger2 and Ann B. Begovich1,‡

1Celera, 1401 Harbor Bay Parkway, Alameda, CA 94502, USA, 2Department of Dermatology and 3Department of Human Genetics, University of Utah, Salt Lake City, UT 84132, USA and 4LineaGen Research Corporation, Salt Lake City, UT 84101, USA

Received March 26, 2008; Revised and Accepted July 7, 2008

Predisposition to psoriasis is known to be affected by genetic variation in HLA-C, IL12B and IL23R, but other genetic risk factors also exist. We recently reported three psoriasis-associated single nucleotide polymorphisms (SNPs) in the 5q31 locus, a region of high linkage disequilibrium laden with inflammatory pathway genes. The aim of this study was to assess whether other variants in the 5q31 region are causal to these SNPs or make independent contributions to psoriasis risk by genotyping a comprehensive set of tagging SNPs in a 725 kb region bounded by IL3 and IL4 and testing for disease association. Ninety SNPs, capturing 86.4% of the genetic diversity, were tested in one case–control sample set (467 cases/460 controls) and significant markers (Pallelic < 0.05) (n = 9) were then tested in two other sample sets (981 cases/925 controls). All nine SNPs were significant in a meta-analysis of the combined sample sets. Pair-wise conditional association tests showed rs1800925, an intergenic SNP located just upstream of IL13 (Mantel–Haenszel Pcombined = 1.5 × 10^−4, OR = 0.77 [0.67–0.88]), could account for observed significant association of all but one other SNP, rs11568506 in SLC22A4 [Mantel–Haenszel Pcombined = 0.043, OR = 0.68 (0.47–0.99)]. Haplotype analysis of these two SNPs showed increased significance for the two common haplotypes (rs11568506–rs1800925: GC, Pcombined = 5.67 × 10^−6, OR = 1.37; GT, Pcombined = 6.01 × 10^−8, OR = 0.75; global haplotype P = 8.93 × 10^−5). Several 5q31-region SNPs strongly associated with Crohn’s disease (CD) in the recent WTCCC study were not significant in the psoriasis sample sets tested here. These results identify the most significant 5q31 risk variants for psoriasis and suggest that distinct 5q31 variants contribute to CD and psoriasis risk.

INTRODUCTION

Genome-wide association (GWA) studies have proven powerful in identifying single nucleotide polymorphisms (SNPs) that are significantly associated with common, multi-factorial diseases (1–3). However, given the nature of these scans, the identified markers may not be causal but rather in linkage disequilibrium (LD) with the true causative variants located elsewhere, possibly in a neighboring, unrelated gene. Furthermore, there may be multiple variants in a region that, independently or together, contribute to disease risk (4,5). Consequently, comprehensive follow-up fine mapping of significant GWA markers, which incorporates the rich genetic information revealed by the HapMap project (6), is required to narrow the region of interest and identify true causal variant(s).
Psoriasis is a common, chronic inflammatory skin disease that can affect individuals of all ages with the majority manifesting clinical symptoms before the age of 40 years (7). Susceptibility to psoriasis is strongly influenced by genetic factors, independently or interacting with each other, and may be initiated or exacerbated by environmental factors such as infection. Haplotypes carrying the HLA-Cw*0602 allele confer the strongest genetic effect in whites, particularly among early onset cases (8,9). More recently, association of psoriasis with SNPs in IL12B and IL23R has been identified (2,10) and independently confirmed in other case–control studies (11–13). Thus, a total of three psoriasis risk loci have been established with convincing statistical evidence.

These genetic variations, however, do not explain the totality of psoriasis risk, suggesting other genetic risk factors exist. Indeed, linkage studies have provided evidence suggesting other genomic loci are significantly associated with this disease (14). In addition, numerous putative risk factors have been reported, often with substantial appeal as strong biological and/or positional candidates (reviewed in 15,16). Recent data have provided evidence for heterogeneity of effect across sample sets for one marker, rs11568506 [odds ratio (OR) homogeneity: \( P_{\text{comb}} = 0.032, P > 0.05 \) for all other markers]. Based on the \( P_{\text{comb}} \)-values, none of the nine new markers were more significant than rs1800925 (Mantel–Haenszel \( P_{\text{comb}} = 0.00015 \), the most significant marker identified in our original report (21), although some were comparable (e.g. \( P = 0.00022 \) for the IL4 marker rs2227282). ORs conferred by these variants were all modest (Table 1 and Supplementary Material, Table S2).

**RESULTS**

**Single marker analysis identifies multiple SNPs associated with psoriasis**

Examination of the 5q31 LD structure in the CEU HapMap Phase II dataset led us to focus our fine mapping on a 725 kb region extending from 50 kb upstream of IL3 to 50 kb downstream of IL4. Ninety fine mapping SNPs, primarily selected as tagging markers (see Materials and methods), were genotyped in 467 cases and 460 controls (sample set 1) (Fig. 1A). In addition to the three original IL13-region SNPs (21), allelic association tests of the 90 new SNPs identified nine additional markers significantly associated with psoriasis (\( P_{\text{allelic}} < 0.05 \), Fig. 1A and Supplementary Material, Table S1) in a 370 kb region extending from SLIC22A4 to KIF3A and including IRF1, IL5, IL13 and IL4. These nine SNPs were then genotyped in two other case–control sample sets (sample set 2: 498 cases/498 controls; sample set 3: 483 cases/427 controls) and although the significance of these nine markers varied in the two follow-up sample sets (Fig. 1A and Supplementary Material, Table S2), all nine were significant in a combined analysis of the three sample sets (Mantel–Haenszel \( P_{\text{comb}} < 0.05 \), Table 1 and Supplementary Material, Table S2). Breslow–Day tests provided no evidence for heterogeneity of effect across sample sets except for one marker, rs11568506 [odds ratio (OR) homogeneity: \( P_{\text{comb}} = 0.032, P > 0.05 \) for all other markers]. Based on the \( P_{\text{comb}} \)-values, none of the nine new markers were more significant than rs1800925 (Mantel–Haenszel \( P_{\text{comb}} = 0.00015 \), the most significant marker identified in our original report (21), although some were comparable (e.g. \( P = 0.00022 \) for the IL4 marker rs2227282). ORs conferred by these variants were all modest (Table 1 and Supplementary Material, Table S2).

**Conditional analysis reveals two independent SNPs**

To tease apart association signals from patterns of LD and determine which of these 12 significant SNPs were independently associated with psoriasis risk, we performed pair-wise genotype-conditioned analyses. Using the combined datasets, we calculated a summary statistic for each pair of SNPs using the genotypes of one marker conditioned on another marker, and evaluated the significance of each result using a permutation test (10,000 permutations) (Table 2). This approach is similar to the haplotype method (22) and has been described previously (2). Not surprisingly, the significant association of various SNPs with psoriasis disappeared upon conditioning on other markers. Most notably, the significance of all other markers except rs11568506 (in SLIC22A4; \( P = 0.0105 \)) was abolished upon conditioning on rs1800925. Conversely, association of rs1800925 remained strong (\( P = 0.0002 \)) upon conditioning on rs11568506. Together these data suggest that rs11568506 and rs1800925 make independent contributions to psoriasis risk. The genotype correlation between rs11568506 and rs1800925 is very low (\( r^2 = 0.006 \), whereas that between rs1800925 and the other 10 SNPs varied from 0.016 to 0.801 (Supplementary Material, Table S3).

Next we assessed whether SNPs in high LD with rs1800925 could be more significantly associated with disease. Genotype data were retrieved from the HapMap CEU dataset (release no. 22, phase II April 07), covering 1 Mb on each side of the IL13 gene, and the correlation (as determined by \( r^2 \) values) between rs1800925 and all 1559 SNPs was calculated. A total of 32 markers, including five SNPs in putative transcription factor binding sites but no cSNPs, were highly correlated with rs1800925 (\( r^2 > 0.8 \) (Supplementary Material, Table S4), 30 of which were in absolute LD (\( r^2 = 1 \)) with one another. One of these 30 markers, rs2897443 (\( r^2 \) with rs1800925 = 0.897) had been genotyped in all three psoriasis sample sets (Supplementary Material, Table S2) and was nearly 10-fold less significant than rs1800925 (\( P_{\text{rs2897443}} = 0.001 \) versus \( P_{\text{rs1800925}} = 0.00015 \)). In addition, rs2897443 was no longer significant after
conditioning on rs1800925 \((P = 0.2168)\), whereas rs1800925 remained significant after conditioning on rs2897443 \((P = 0.0423)\). The remaining two markers (rs2706370 and rs12187537) were not genotyped in our study; however, they were more highly correlated with rs2897443 \((r^2 = 0.94)\) than with rs1800925 \((r^2 = 0.829\) and 0.817, respectively) suggesting their association with psoriasis is most likely less significant than rs1800925. All together, these data indicate that there is no evidence that any of the HapMap SNPs are more significantly associated with psoriasis than rs1800925.

Given that two markers, rs11568506 and rs1800925, show independent association with psoriasis, we carried out haplotype analyses using both markers in each of the three individual sample sets and in a combined analysis of all three sample sets. Although it is difficult to determine whether the two independent markers reside in the same LD block (Fig. 1B), the number of double heterozygotes was small (7 cases and 16 controls out of 2800 samples; Supplementary Material, Table S5); therefore, phase could be unambiguously established in 99.2\% of all individuals. Three haplotypes were observed, with the fourth being relatively rare \((<0.001\) in cases or controls) due to the low frequency of rs11568506. The two common haplotypes were significantly associated with psoriasis in two of the three
sample sets; although they were not significant in sample set 2, the ORs were in the same direction as in the other two sample sets (Table 3). In a meta-analysis, both common haplotypes were significantly associated with psoriasis, and significance of the most common haplotype, GC, was markedly higher than any single SNP (OR = 5.67 × 10^{-6} for the haplotype versus 1.5 × 10^{-4} for rs1800925). The observed effect sizes in the combined analysis of all sample sets were 1.37 for the predisposing GC (rs11568506–rs1800925) haplotype (frequency: 0.156 in cases, 0.827 in cases versus 0.777 in controls) and 0.75 for the protective GT haplotype (frequency: 0.156 in cases, 0.198 in controls).

**Distinct SNPs are associated with psoriasis and Crohn’s disease (CD)**

Previous studies have identified linkage of the 5q31 locus and/or association of specific variants in this region with several other diseases, including CD and asthma/allergic disorders (23–25). Because psoriasis and CD may share a common genetic etiology, association of specific variants in this region with several other diseases, including CD and asthma/allergic disorders (23–25), we tested the association of two independent, psoriasis-associated SNPs in the three sample sets combined.

### Table 1. Association analysis of the two independent, psoriasis-associated SNPs in the three sample sets combined

<table>
<thead>
<tr>
<th>SNP ID</th>
<th>Gene</th>
<th>Allele/Genotype</th>
<th>Cases, n (%)</th>
<th>Controls, n (%)</th>
<th>OR (95% CI)</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>rs11568506</td>
<td>SLC22A4</td>
<td>A</td>
<td>50 (0.017)</td>
<td>69 (0.025)</td>
<td>0.68 (0.47–0.99)</td>
<td>0.043</td>
</tr>
<tr>
<td></td>
<td></td>
<td>G</td>
<td>2820 (0.983)</td>
<td>2677 (0.975)</td>
<td>1.00 (reference)</td>
<td>NC</td>
</tr>
<tr>
<td></td>
<td></td>
<td>A</td>
<td>2 (0.0014)</td>
<td>0 (0)</td>
<td>0.63 (0.43–0.92)</td>
<td>0.022</td>
</tr>
<tr>
<td></td>
<td></td>
<td>AG</td>
<td>46 (0.032)</td>
<td>69 (0.050)</td>
<td>1.00 (reference)</td>
<td>0.00015</td>
</tr>
<tr>
<td></td>
<td></td>
<td>GG</td>
<td>1387 (0.0967)</td>
<td>1304 (0.950)</td>
<td>0.77 (0.67–0.88)</td>
<td>0.00081</td>
</tr>
<tr>
<td>rs1800925</td>
<td>IL13</td>
<td>T</td>
<td>453 (0.158)</td>
<td>540 (0.196)</td>
<td>0.78 (0.66–0.92)</td>
<td>0.022</td>
</tr>
<tr>
<td></td>
<td></td>
<td>C</td>
<td>2417 (0.842)</td>
<td>2210 (0.804)</td>
<td>0.77 (0.67–0.88)</td>
<td>0.00081</td>
</tr>
<tr>
<td></td>
<td></td>
<td>TT</td>
<td>36 (0.025)</td>
<td>56 (0.041)</td>
<td>0.78 (0.66–0.92)</td>
<td>0.022</td>
</tr>
<tr>
<td></td>
<td></td>
<td>TC</td>
<td>381 (0.266)</td>
<td>428 (0.311)</td>
<td>0.78 (0.66–0.92)</td>
<td>0.022</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CC</td>
<td>1018 (0.709)</td>
<td>891 (0.648)</td>
<td>1.00 (reference)</td>
<td>NC</td>
</tr>
</tbody>
</table>

aData for the 10 other significant SNPs are presented in Supplementary Material, Table S2.

**DISCUSSION**

Our analysis of the 5q31 cytokine cluster reveals that multiple SNPs are significantly associated with psoriasis risk; however, incorporating LD into our analysis revealed two independent, psoriasis-associated SNPs: rs1800925 located 5' of *IL13* and rs11568506, an intronic SNP in *SLC22A4*, also known as organic cation transporter 1 (*OCTN1*). The observed significance was only marginal for the *SLC22A4* marker (Mantel–Haenszel $P_{combined} = 0.043$). However, combining the genotype information for this marker with the more frequent *IL13* marker, which is also more significant (Mantel–Haenszel $P_{combined} = 0.00015$), resulted in two common psoriasis-associated haplotypes that were both highly significant. In particular, the major risk haplotype, with a control allele frequency of 0.777 increasing to 0.827 in cases, showed more pronounced association with psoriasis ($P_{combined} = 5.67 × 10^{-6}$, OR = 1.37) than any of the individual markers.

The biological interpretation of this observation (i.e. variants in two linked genes) is not straight-forward; however, both *SLC22A4* and *IL13* are putative genetic risk factors for other autoimmune or autoinflammatory disorders. Specifically, two-locus functional polymorphisms (haplotypes) in *SLC22A4* and the adjacent *SLC22A5* genes have been reported to be associated with CD (27), although definitive causal variants remain to be determined (28,29). Variation in *IL13*, which encodes an immunoregulatory cytokine produced by activated T helper 2-type (Th2) cells, has been most prominently associated with asthma (23), as well as atopic dermatitis (30). Thus, both genes have strong *a priori* plausibility as risk factors of psoriasis, particularly as the evidence for shared risk variants across multiple autoimmune disorders increases (31,32).
Table 2. Conditional association tests for rs2 markers. P-values for marker 1 conditional on marker 2

| Marker 1 | rs11568506 | rs11568506 | rs126243218 | rs126243218 | rs126243218 | rs126243218 | rs126243218 | rs126243218 | rs126243218 | rs126243218 | rs126243218 | rs126243218 | rs126243218 | rs126243218 | rs126243218 |
|----------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|
| Marker 2 | rs11568506  | 0.0012      | 0.0012      | 0.0012      | 0.0012      | 0.0012      | 0.0012      | 0.0012      | 0.0012      | 0.0012      | 0.0012      | 0.0012      | 0.0012      | 0.0012      | 0.0012      | 0.0012      |
|          | rs11568506  | 0.0012      | 0.0012      | 0.0012      | 0.0012      | 0.0012      | 0.0012      | 0.0012      | 0.0012      | 0.0012      | 0.0012      | 0.0012      | 0.0012      | 0.0012      | 0.0012      | 0.0012      |
|          | rs11568506  | 0.0012      | 0.0012      | 0.0012      | 0.0012      | 0.0012      | 0.0012      | 0.0012      | 0.0012      | 0.0012      | 0.0012      | 0.0012      | 0.0012      | 0.0012      | 0.0012      | 0.0012      |
|          | rs11568506  | 0.0012      | 0.0012      | 0.0012      | 0.0012      | 0.0012      | 0.0012      | 0.0012      | 0.0012      | 0.0012      | 0.0012      | 0.0012      | 0.0012      | 0.0012      | 0.0012      | 0.0012      |

P-values for marker 1 conditional on marker 2

- **P < 0.05 in boldface.**

The two identified SNPs are located in an intron of SLC22A4 and near the 5'-end of IL13, respectively. There is no predictive functional significance based on current SNP annotation, although rs11568506 is 43 bp from a POU2F1 transcription factor binding site, which exhibits a high degree of conservation across multiple placental mammals. In the absence of a validated role for these SNPs in gene regulation, there are several other excellent biological candidate genes within this region as well as critical regulatory elements (33), it is tempting to speculate that untested, causal genetic variant(s) in the region could be responsible for modulating disease susceptibility.

The recent identification of IL23R variants associated with psoriasis and CD solidifies the notion that genetic etiology may overlap between these two diseases (1,2). However, even though 5q31 linkage signals have been observed for both diseases (35–37), our data suggest that distinct markers within this region contribute to CD and psoriasis risk. Several previously reported CD-associated markers in the 5q31 region, including one that tags a risk haplotype (rs6596075), were not significant in our psoriasis sample sets despite having sufficient power to detect an effect size similar to that observed in the CD study (3). In addition, the modest association of rs2522057 with psoriasis in the combined analysis of our sample sets could be explained by LD with other SNPs not available in the HapMap, such as our most significant marker, rs1800925. This observation results. Similarly, other genetic variants (insertions, deletions, etc.) which have been implicated in the etiology of various complex diseases, including psoriasis (17,34), may be responsible for modulating disease susceptibility.

Finally, it is possible that we may not have the power to detect independent effects in our sample sets. Thus, although the significance of all other markers except rs11568506 can be accounted for by rs1800925, we cannot exclude the possibility that other markers, particularly the stronger ones in IL13 and IL4, make additional, independent contributions to disease risk. In addition, the possibility that our current finding is false positive cannot be completely discounted, since the observed
significance will not survive multiple testing corrections if all markers tested in our previous genome-wide scan and in this study are considered—which is generally deemed conservative. However, in an unpublished GWA study of 1,400 white North American cases and 1,400 white North American controls, two of our original IL13-associated SNPs, rs20541 and rs848, exhibit very strong evidence for association (Abecasis, Bowcock, Krueger and Elder, personal communication). These data suggest markers in the 5q31 region are true psoriasis risk markers; validation in other sample sets of similar characteristics is warranted to bring further definition to the causal variant(s).

MATERIALS AND METHODS

Clinical samples

Three sample sets of psoriasis cases and unaffected controls were assembled for this study. Detailed demographics and diagnostic/enrollment criteria have been described in a previous publication (2). Briefly, all individuals are North American whites of European descent and were 18 years or older when they contributed their samples (sample set 1: 467 cases/460 controls; sample set 2: 498 cases/498 controls; sample set 3: 483 cases/427 controls). Informed written consent was obtained from all participants, and all protocols were approved by national and/or local institutional review boards.

Selection of tagging SNPs and overall study design

To comprehensively yet efficiently investigate the 5q31 region, we ran the MIT tagger program (http://www.broad.mit.edu/mpg/tagger/server.html) (39) with the CEU HapMap phase II dataset [the landmarks were set at chr5:131373131...132097638 bp (NCBI Build 36); minimal allele frequency was set at 0.02; r² threshold was set at 0.8; and tagging mode was set at pair-wise]. A total of 103 tagging SNPs (including the previously tested IL13 marker rs20541) are required to capture the SNP diversity (610 polymorphic sites) within this 725 kb region. Assay designs were attempted on the default tagging markers, and when not feasible, on an alternative marker within the tagging group. We referenced the WTCCC study to preferentially select markers that were significantly associated with CD as tagging markers. We were able to develop assays for 90 of these tagging SNPs (excluding the assay already available for rs20541). In addition, assays for two SNPs in predicted transcription factor binding sites (rs381870 and rs4540166) were developed.

The above 92 SNPs were genotyped in one of the three psoriasis case–control sample sets (sample set 1; 467 cases/460 controls). Genotyping data for 90 markers, including 88 tagging markers (equivalent to 86.4% coverage for all tagging markers), passed quality control and were subjected to further analysis. Hardy–Weinberg equilibrium tests identified six markers in controls and two others in cases with P < 0.05 (Supplementary Material, Table S1). However,

---

**Table 3. Haplotype association tests**

<table>
<thead>
<tr>
<th>Sample set</th>
<th>Haplotype (rs11568506/rs1800925)</th>
<th>Cases, n (%)</th>
<th>Controls, n (%)</th>
<th>Phaplotype</th>
<th>Global P</th>
<th>OR</th>
</tr>
</thead>
<tbody>
<tr>
<td>SS1</td>
<td>GC</td>
<td>771 (0.844)</td>
<td>713 (0.787)</td>
<td>0.0019</td>
<td>0.0028</td>
<td>1.46</td>
</tr>
<tr>
<td></td>
<td>GT</td>
<td>131 (0.143)</td>
<td>167 (0.184)</td>
<td>0.018</td>
<td>0.74</td>
<td>0.45</td>
</tr>
<tr>
<td></td>
<td>AC</td>
<td>12 (0.013)</td>
<td>26 (0.029)</td>
<td>0.019</td>
<td></td>
<td></td>
</tr>
<tr>
<td>SS2</td>
<td>GC</td>
<td>796 (0.807)</td>
<td>765 (0.781)</td>
<td>0.13</td>
<td>0.11</td>
<td>1.18</td>
</tr>
<tr>
<td></td>
<td>GT</td>
<td>168 (0.170)</td>
<td>199 (0.203)</td>
<td>0.052</td>
<td>0.81</td>
<td></td>
</tr>
<tr>
<td></td>
<td>AC</td>
<td>22 (0.022)</td>
<td>15 (0.015)</td>
<td>0.36</td>
<td>1.48</td>
<td></td>
</tr>
<tr>
<td>SS3</td>
<td>GC</td>
<td>799 (0.830)</td>
<td>651 (0.764)</td>
<td>0.00091</td>
<td>0.0028</td>
<td>1.51</td>
</tr>
<tr>
<td></td>
<td>GT</td>
<td>147 (0.153)</td>
<td>175 (0.205)</td>
<td>0.0069</td>
<td>0.70</td>
<td></td>
</tr>
<tr>
<td></td>
<td>AC</td>
<td>13 (0.014)</td>
<td>26 (0.031)</td>
<td>0.031</td>
<td>0.45</td>
<td></td>
</tr>
<tr>
<td>Allb</td>
<td>GC</td>
<td>2366 (0.827)</td>
<td>2128 (0.777)</td>
<td>5.67E−06</td>
<td>8.93E−05</td>
<td>1.37</td>
</tr>
<tr>
<td></td>
<td>GT</td>
<td>446 (0.156)</td>
<td>542 (0.198)</td>
<td>6.01E−05</td>
<td>0.75</td>
<td></td>
</tr>
<tr>
<td></td>
<td>AC</td>
<td>47 (0.017)</td>
<td>68 (0.025)</td>
<td>0.053</td>
<td>0.66</td>
<td></td>
</tr>
</tbody>
</table>

*aFrequency of AT haplotype is <0.001 in both cases or controls.

*bHaplotype counts were estimated and may vary slightly from the sum of the three individual sample sets.

**Table 4. Association of putative CD SNPs with psoriasis**

<table>
<thead>
<tr>
<th>Marker</th>
<th>Chr</th>
<th>Position (bp)</th>
<th>Gene</th>
<th>Psoriasis (SS1+SS2+SS3) Allele frequency</th>
<th>CD (WTCCC)² Allele frequency</th>
<th>Pallelic Case</th>
<th>OR (95% CI)</th>
<th>Pallelic Case</th>
<th>OR (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>rs6596075</td>
<td>5</td>
<td>131 770 127</td>
<td>LOC441108</td>
<td>0.162/0.164</td>
<td>0.127/0.166</td>
<td>0.82</td>
<td>0.98 (0.85−1.14)</td>
<td>0.127/0.166</td>
<td>5.40E−07 0.73 (0.65−0.83)</td>
</tr>
<tr>
<td>rs2285673</td>
<td>5</td>
<td>131 783 868</td>
<td>LOC441108</td>
<td>0.205/0.212</td>
<td>0.189/0.228</td>
<td>0.43</td>
<td>0.95 (0.84−1.08)</td>
<td>0.212/0.252</td>
<td>1.50E−05 0.80 (0.73−0.89)</td>
</tr>
<tr>
<td>rs4540166</td>
<td>5</td>
<td>131 807 752</td>
<td>LOC441108</td>
<td>0.205/0.212</td>
<td>0.189/0.228</td>
<td>0.52</td>
<td>0.96 (0.84−1.09)</td>
<td>0.212/0.252</td>
<td>1.50E−05 0.80 (0.73−0.89)</td>
</tr>
<tr>
<td>rs10077785</td>
<td>5</td>
<td>131 829 057</td>
<td>LOC441108</td>
<td>0.205/0.212</td>
<td>0.189/0.228</td>
<td>0.45</td>
<td>0.95 (0.84−1.09)</td>
<td>0.212/0.252</td>
<td>1.50E−05 0.80 (0.73−0.89)</td>
</tr>
<tr>
<td>rs2522057</td>
<td>5</td>
<td>131 829 846</td>
<td>LOC441108</td>
<td>0.444/0.414</td>
<td>0.478/0.422</td>
<td>0.022</td>
<td>1.13 (1.02−1.26)</td>
<td>0.478/0.422</td>
<td>1.01E−07 1.29 (1.20−1.33)</td>
</tr>
</tbody>
</table>

²Data are from WTCCC (3).
analysis of the data showed no apparent error in genotype assignment for these markers, thus they were included in the association tests. As predicted, inter-marker LD between the genotyped markers was low in our samples (Fig. 1B). Significant SNPs (P < 0.05) were then genotyped in two other case–control sample sets [sample set 2 (498 cases/498 controls) and sample set 3 (483 cases/424 controls)].

Genotyping
Genotyping was carried out by the method of real-time, allele-specific PCR with primers designed and validated in-house (40) (primer information is available upon request). Genotype calls of cases and controls, randomly arrayed onto genotyping plates, were made using an automated algorithm and were subjected to manual examination without knowledge of case–control status, prior to statistical analysis. Genotyping accuracy has been consistently better than 99% (2,41).

Statistical analysis
Hardy–Weinberg equilibrium was examined by an exact test. Allelic association of SNPs with psoriasis risk was determined using fixed effects of Mantel–Haenszel methods to combine ORs across the sample sets. Marker conditional association tests were done using an approach similar to the haplotype method (22) as previously described (2). In brief, cases and controls were partitioned on the basis of genotypes at one SNP, and counts at an interrogated SNP were subjected to analysis, where statistical significance was assessed by a permutation method (10 000 permutations). The marker–marker LD, D' and r² were calculated using LDMax (www.sph.umich.edu/csg/abecasis/GOLD/docs/ldmax.html). Haplotypes were estimated and tested for association with disease status using a score test with haplotypes coded in an additive fashion (42). Power calculations were done using the PS:Power and Sample Size Calculation Program, obtained from the Department of Biostatistics, Vanderbilt University website (http://biostat.mc.vanderbilt.edu/twiki/bin/view/Main/PowerSampleSize).

SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG Online.

ACKNOWLEDGEMENTS

Conflict of Interest statement. Authors employed by Celera declare their financial interest in the company.

REFERENCES


